You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 21-40 of 182 results found

Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)

Researchers at the National Cancer Institute (NCI) have developed an invention consisting of hydrocarbon stapled peptides that disrupt the linear ubiquitin-chain assembly complex (LUBAC), which is involved in NF-κB signaling. These peptides can be used as a therapeutic in the treatment of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma, as well as inflammatory diseases. The NCI seeks licensing and/or co-development research collaborations for inhibitors of NF-κB signaling and/or treatment of ABC DLBCL, as well as inflammatory diseases.
  • Therapeutics

Cancer Inhibitors Isolated from an African Plant

The National Cancer Institute's Molecular Targets Development Program is seeking parties interested in collaborative research to further develop, evaluate, or commercialize cancer inhibitors isolated from the African plant Phyllanthus englerii. The technology is also available for exclusive or non-exclusive licensing.
  • Therapeutics

Nucleic Acid Nanoparticles for Triggering RNA Interference

RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases. The National Cancer Institute seeks partners to license or co-develop RNA, RNA-DNA, and DNA-RNA hybrid nanoparticles consisting of a DNA or RNA core with attached RNA or DNA hybrid duplexes.
  • Therapeutics

Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents

IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. The National Cancer Institute seeks parties interested in licensing or collaborative research to co-develop selective IL-10 and IFN-gamma peptide inhibitors.
  • Therapeutics

Polypeptides for Stimulation of Immune Response (Adjuvants)

Researchers at the National Cancer Institute, Laboratory of Molecular Immunoregulation developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens.The National Cancer Institute, Laboratory of Molecular Immunoregulation seeks parties interested in licensing or collaborative research to co-develop polypeptides or antagonists for immune response regulation.
  • Therapeutics

Phosphodiesterase as a target for cancer therapeutics

Investigators at the National Cancer Institute have discovered fluoroquinolone derivatives as specific Tdp1 inhibitors that could potentiate the pharmacological action of Top1 inhibitors currently used in cancer treatment.
  • Therapeutics

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.
  • Therapeutics

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity. The National Cancer Institute's Laboratory of Molecular Biology seeks interested parties to co-develop and commercialize immunotoxins using toxin domains lacking human B cell epitopes.
  • Therapeutics

Pages